
What you need to know
- Stryker said on 12 October 2026 it will make a preferred equity investment of approximately USD 400 million (GBP 300 million) in Cambridge-based CMR Surgical.
- The investment carries an exclusive option for Stryker to acquire 100 per cent of CMR in the future and makes Stryker the exclusive US sales agent for the Versius robot.
- The stake size, valuation, option price and closing date were not disclosed, and the deal still needs regulatory approvals.
Stryker, the Michigan-based medical technology group, said on 12 October 2026 that it will make a preferred equity investment of approximately USD 400 million (GBP 300 million) in CMR Surgical, the Cambridge company that makes the Versius surgical robot. The investment gives Stryker an exclusive option to acquire 100 per cent of CMR’s outstanding equity in the future, subject to the terms of the agreement, and makes Stryker the exclusive US sales agent for the Versius portfolio.
The companies did not disclose the size of the stake the money buys, the valuation, the price at which the option could be exercised or the period in which it can be used. The transaction is subject to regulatory approvals and customary closing conditions, and no closing date was given.
What each side gets
Under the joint announcement, CMR will continue to lead development of the Versius portfolio and its commercialisation in markets outside the United States, while Stryker takes over US selling. CMR chief executive Massimiliano Colella said the company looks forward to welcoming Andy Pierce, Stryker’s Group President, Medsurg and Neurotechnology, to its board of directors.
Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies.
Andy Pierce, Group President, Medsurg and Neurotechnology, Stryker
The companies describe Versius as a second-generation robot that supports a broad range of soft-tissue procedures, with a modular design that they say can help providers grow robotic adoption within existing operating room workflows. Pierce said Stryker selected CMR because of the opportunity to help providers grow robotic-assisted surgery across a broad range of procedures in hospitals and ambulatory surgery centres.
Where CMR stood before the deal
CMR, founded in 2014, said in March 2026 that more than 45,000 patients had been treated with Versius and that the system had been adopted by hospitals in more than 30 countries. At that point it was starting a US launch after the US Food and Drug Administration cleared the next-generation Versius Plus system in December 2025 for cholecystectomy (gallbladder removal), according to the company. CMR’s US website states that Versius Plus is indicated for adult patients aged 22 and over who are eligible for soft-tissue minimal access surgery, for cholecystectomy.
The Stryker money follows a financing of more than USD 200 million that CMR announced in April 2025, combining equity and debt. The company said at the time that the round was supported by all its existing major investors, included a new debt investment from Trinity Capital, and would fund commercial expansion with a major focus on launching in the United States.
Our reading
- The Healthcare Daily’s reading: the structure lets Stryker enter soft-tissue robotics without buying the whole company now, while CMR gets capital and access to Stryker’s US commercial reach in one step. For a UK-headquartered business, the option means control could pass to a US group later, on terms that have not been made public.
- For NHS trusts and private hospital groups in the UK, India and the Gulf, CMR remains the seller outside the United States. Buyers with Versius contracts or tenders in progress may want to ask how service, pricing and product plans would be handled if the option is exercised, a point the announcement does not address.
- Investors cannot yet put a value on CMR from this deal. Neither party disclosed the equity percentage or how the option price will be set, so the April 2025 round and this one cannot be compared on valuation.
Questions readers ask
How much is Stryker investing in CMR Surgical?
Stryker said on 12 October 2026 that it will make a preferred equity investment of approximately USD 400 million (GBP 300 million) in CMR Surgical. The size of the stake and the valuation were not disclosed.
Does Stryker now own CMR Surgical?
No. The investment gives Stryker an exclusive option to acquire 100 per cent of CMR's outstanding equity in the future, subject to the agreement's terms, and the transaction still needs regulatory approvals and customary closing conditions.
Who will sell the Versius robot outside the United States?
CMR Surgical will continue to lead development and commercialisation of the Versius portfolio in markets outside the United States. Stryker becomes the exclusive US sales agent.
Approval status and any claim about a product’s effect are as stated by the regulator or company named in the sources, for the jurisdiction stated. This is a business publication, not medical advice.
Sources
Announced plans, figures and dates are as stated in the sources below at the time of publication and can change. Conclusions drawn from them are our reading.
- Stryker and CMR Surgical: Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery (12 October 2026)
- CMR Surgical: CMR Surgical Announces 45,000 Patients Treated Globally as Robotic-Assisted Surgery Company Makes Its U.S. Debut (26 March 2026)
- CMR Surgical: CMR Surgical secures more than $200M to accelerate growth (4 April 2025)
- Startupmag: CMR Surgical raises £301.9m from Stryker (14 October 2026)
Topics
Follow The Healthcare Daily on Google News
New stories appear where you already read the news.
The Healthcare Daily. We report from primary sources and list them on every story.


